Additionally, in scenarios when PD-L1 and CTLA-4 expression is low, high tumor mutational burden (TMB) can also serve as a biomarker for immunotherapy response, with a higher TMB resulting in more neo-antigens that enhance T-cell reactivity and improve treatment outcomes [10,11]. The gene discussed is CD274; the disease is neoplasm.